NanoPass Technologies to Supply MicronJet600™ Device to Immune Design for Use in ZVex-based Oncology Immunotherapy Products NanoPass Technologies Ltd. (“NanoPass”), a pioneer in intradermal delivery solutions for immunotherapies, announced today that it has entered into a clinical supply and support agreement for the supply of MicronJet600™, its microneedle delivery device, for use with Immune
Gamida Cell plans to commence Phase III study of NiCord in 2016Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, announced today that the company has reached agreements with the FDA and EMA regarding the Phase III study design outline of NiCord. The company is moving
ReWalk Robotics Launches ReWalk 6.0: the Company’s Sixth Generation Personal System for Home & Community UseThis Version of the ReWalk Personal Exoskeleton Offers Users the Fastest Walking Speed, Most Natural Gait, and the Most Precise Fit of Any ExoskeletonYOKNEAM ILIT, ISRAEL / MARLBOROUGH, MASSACHUSETTS, July 14, 2015 — ReWalk Robotics Ltd. (Nasdaq: RWLK), the leading
NanoPass Technologies Grants an Exclusive License to Circassia Pharmaceuticals, for use of its MicronJet600™ Device in Allergy Testing in the USNanoPass Technologies Ltd. (“NanoPass”), a pioneer in intradermal delivery solutions for vaccines, announced today that it has entered into a license agreement for the supply of MicronJet600™, its microneedle delivery device, to Circassia Pharmaceuticals plc.
ReWalk Robotics Announces Expansion to India with Saimed InnovationsAgreement Will Launch First Ever Exoskeleton Rehabilitation Programs, Distribution in Northern IndiaMarlborough, MA/Kolkata, India — Exoskeleton leader ReWalk Robotics announced today a new partnership with Saimed Innovations, a leading medical technologies provider, to distribute the ReWalk exoskeleton systems in Northern India. This agreement marks a milestone for